Search research articles
Contact Us
Filters
Showing results (91-100 of 129) with videos related to
Page
of 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1991
Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques)
M Riggi, P Ruffie, S Voisin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment
F Saliba, R Hagipantelli, J L Misset, et al.
Anti-Cancer Drugs
|
June 13, 1998
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters
E Gamelin, M Boisdron-Celle, A Lebouil, et al.
Cancer
|
November 15, 1991
Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease
G Recondo, E Cvitkovic, N Azli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 1999
Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience
S Faivre, S Kalla, E Cvitkovic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2001
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients
F Goldwasser, M Gross-Goupil, J M Tigaud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 16, 1998
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques
I Monnet, S Brienza, F Hugret, et al.
Journal of the National Cancer Institute
|
April 17, 1991
Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer
J N Munck, E Cvitkovic, J D Piekarski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 1999
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients
N Germann, S Brienza, M Rotarski, et al.
Anti-Cancer Drugs
|
December 13, 1997
Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer
P Soulié, L Trandafir, A Taamma, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 129) with videos related to
Sort By:
Page
of 13
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1991
Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques)
M Riggi, P Ruffie, S Voisin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment
F Saliba, R Hagipantelli, J L Misset, et al.
Anti-Cancer Drugs
|
June 13, 1998
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters
E Gamelin, M Boisdron-Celle, A Lebouil, et al.
Cancer
|
November 15, 1991
Neoadjuvant chemotherapy consisting of cisplatin and continuous infusions of bleomycin and 5-fluorouracil for advanced head and neck cancer. The need for a new stratification for stage IV (M0) disease
G Recondo, E Cvitkovic, N Azli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 26, 1999
Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience
S Faivre, S Kalla, E Cvitkovic, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 6, 2001
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients
F Goldwasser, M Gross-Goupil, J M Tigaud, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 16, 1998
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques
I Monnet, S Brienza, F Hugret, et al.
Journal of the National Cancer Institute
|
April 17, 1991
Computed tomographic density of metastatic lymph nodes as a treatment-related prognostic factor in advanced head and neck cancer
J N Munck, E Cvitkovic, J D Piekarski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 1999
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients
N Germann, S Brienza, M Rotarski, et al.
Anti-Cancer Drugs
|
December 13, 1997
Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer
P Soulié, L Trandafir, A Taamma, et al.
Page
of 13